New Eye Injection Treatment for Age-Related Macular Degeneration
Part of Eyes & vision clinical trials.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 or older
- Wet AMD in one or both eyes that has never been treated before
- Active fluid in the retina (the light-sensitive tissue in the back of your eye) confirmed by eye imaging
- Vision between 24 and 78 letters on an eye chart (roughly 20/320 to 20/32)
- No prior eye injections, laser treatment, or surgery for this condition
- Blood pressure controlled and stable for at least 12 weeks before joining
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two eye injection treatments for wet age-related macular degeneration (AMD), a condition that causes vision loss. The trial aims to see if the new drug GNR-139 works as well as the standard treatment Eylea.
This study tests a new experimental eye drop (EYC-0305) for wet AMD, a common cause of vision loss in older adults. The goal is to see if it can slow or prevent further damage to central vision.
This study tests an investigational drug given as an eye injection to treat wet age-related macular degeneration (AMD) in people who have not been treated before. The goal is to see if it can help improve vision and reduce the need for frequent injections.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This study tests a new eye injection (called QL1207H) against aflibercept, a standard treatment for wet macular degeneration. The goal is to see if the new drug is as effective in improving vision and reducing fluid in the eye.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
Hear when a new Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.